News

Palisade Bio Advances PALI-2108 Dosing for Ulcerative Colitis

Palisade Bio Advances PALI-2108 Dosing for Ulcerative Colitis

Palisade Bio Takes Significant Step in Ulcerative Colitis Treatment

Palisade Bio, Inc. (Nasdaq: PALI) has embarked on an exciting journey as it commences dosing in the first cohort of patients with ulcerative colitis (UC) within its ongoing Phase 1a/b study focusing on PALI-2108. This clinical-stage biopharmaceutical company is dedicated to advancing innovative therapeutics aimed at helping those dealing with autoimmune, inflammatory, and fibrotic diseases.

So far, the preliminary data from the study is encouraging. The results from all five single ascending dose (SAD) cohorts, along with the three completed multiple ascending dose (MAD) cohorts, indicate that PALI-2108 is both safe and well-tolerated. Remarkably, there have been no serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) that connect to laboratory values or electrocardiograms (EKGs), underscoring the promise of this investigational therapy.

Positive Safety Profile and Evolving Study Insights

The initiation of dosing in the final cohort marks a milestone in the study. In addition to the completion of the SAD cohorts, Palisade has also successfully wrapped up the first three MAD cohorts. These results indicate that the observed TEAEs were predominantly mild, with only one withdrawal recorded at the highest MAD dosage. Notably, two of the MAD cohorts were finished within the expected therapeutic dose bracket, again highlighting the absence of SAEs or TEAEs intertwined with lab results or EKGs.

Expert Insight on Progress

Dr. Mitch Jones, the Chief Medical Officer of Palisade, expressed his enthusiasm about transitioning from healthy volunteers to dosing patients with UC. The preliminary outcomes from both the SAD and MAD cohorts have aligned with management’s expectations. Dr. Jones emphasized the importance of these results, saying, "We look forward to additional evaluations and are on track to disclose topline data in the near future," signaling strong anticipation of findings in the coming months.

Understanding PALI-2108 and Its Impact

The key goal of this Phase 1a/b study is to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PALI-2108. This new chemical entity has not been administered to humans in prior studies, making this research particularly critical. The investigation of biomarkers including serum high sensitivity C-reactive protein (hsCRP) and fecal calprotectin (CalPro) will add further depth to the understanding of how PALI-2108 performs.

Key Biomarkers Under Investigation

In addition to the biomarkers mentioned, the study will evaluate colonic tissue histology assessments. This analysis will consider drug and metabolite levels, as well as PDE4 expression and cyclic adenosine monophosphate (cAMP) levels. These factors are integral to grasping the drug’s mechanism and overall efficacy in treating UC.

Looking Ahead: Exciting Future for Palisade Bio

Palisade Bio continues to set a standard in the treatment landscape for individuals living with UC and other related conditions. The positive momentum gained from the study's results might pave the way for PALI-2108 becoming a transformative treatment option for those affected by this challenging disease.

To learn more about the ongoing Phase 1a/b study, interested individuals may find additional details on the clinical trials page.

Frequently Asked Questions

What is PALI-2108?

PALI-2108 is an investigational drug developed by Palisade Bio aimed at treating ulcerative colitis.

What are the main goals of the Phase 1a/b study?

The study aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PALI-2108 in both healthy volunteers and UC patients.

How is the dosing progress so far?

The dosing for the first cohort of UC patients has commenced, with promising preliminary data showing no serious adverse events.

What results have been seen from previous cohorts?

Previous cohorts have shown that PALI-2108 is well tolerated with no significant adverse events reported to date.

What does the future hold for Palisade Bio?

The company is on track to release topline data soon, indicating strong progress in its clinical trials and research endeavors.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 232

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 119

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 266

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 339

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 217

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 201

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 128

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 99

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 163

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 175

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading

Top 5 Most Recently Viewed Articles

Roku Inc. Shares Surge Following Strong Fiscal Report

Updated Category News Views 247

Roku Inc. Shows Resilience in Latest Earnings Report Roku, Inc. (NASDAQ: ROKU) has made headlines recently as its stock takes a positive turn following the release of its fourth-quarter results for the fiscal year 2024. The company's performance exceeded expectations, giving investors and analysts alike a reason to take notice. Strong Earnings Beat Analysts' Predictions...

Continue Reading
Cupshe Dominates Miami Swim Week with Unique Showcase

Updated Category News Views 145

Fashion Meets Storytelling at Miami Swim Week Well, it's official: Cupshe has shown up at Miami Swim Week 2026 with an offering that's turning heads. We're not just talking about another run-of-the-mill runway show. This edition, held at Temple House in Miami Beach, brought an immersive experience dubbed 'The Arrival'. They showcased 45 looks, making a statement with...

Continue Reading
AmeriServ Financial's New Contract Strengthens Workforce Relations

Updated Category News Views 136

AmeriServ Financial's New Labor Contract: A Positive Step Forward AmeriServ Financial Inc. (NASDAQ: ASRV) has successfully forged a new four-year labor contract with the United Steelworkers (USW) Local 2635-06. This recent agreement signifies a proactive approach to employee relationships, ensuring the bank remains a vital part of the community. Details of the Agreement...

Continue Reading
AS Tallink Grupp's Passenger and Cargo Transport Insights

Updated Category News Views 230

Overview of AS Tallink Grupp's May 2025 Performance In May 2025, AS Tallink Grupp reported the transportation of 472,683 passengers, reflecting a slight decline of 2.0% from the previous year. This decrease in passenger numbers is indicative of the ongoing challenges in the transportation sector. Along with passenger counts, the number of cargo units also saw a...

Continue Reading
B2B Food and Beverages E-commerce Market Insights for Future Growth

Updated Category News Views 248

The Expanding Landscape of B2B Food and Beverages E-commerce The B2B food and beverages e-commerce market is on an impressive trajectory, projected to ascend from USD 255.63 billion in 2024 to an astounding USD 1.15 trillion by 2034. This growth is fueled by an increasing demand for online transactions, ease of accessing supplies, and the innovation of diverse food and...

Continue Reading